Zydus Cadila has received the final approval from the USFDA to market Mesalamine Suppositories for rectal use, (US RLD - Canasa) I 000 mg. The drug is used to treat ulcerative proctitis, a type of bowel disease.

It is an aminosalicylate anti-inflammatory drug and believed to work by blocking the production of certain natural chemicals that may cause pain and swelling. This will be manufactured at the group's Topical manufacturing facility at Ahmedabad.

The group now has 280 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)